These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 26456301)

  • 1. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
    Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation.
    Maruyama J; Manning JT; Mateer EJ; Sattler R; Bukreyeva N; Huang C; Paessler S
    mSphere; 2019 Sep; 4(5):. PubMed ID: 31554720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.
    Lingas G; Rosenke K; Safronetz D; Guedj J
    PLoS Comput Biol; 2021 Jan; 17(1):e1008535. PubMed ID: 33411731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
    Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining Ribavirin's mechanism of action against Lassa virus infection.
    Carrillo-Bustamante P; Nguyen THT; Oestereich L; Günther S; Guedj J; Graw F
    Sci Rep; 2017 Sep; 7(1):11693. PubMed ID: 28916737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
    Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S
    Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current research for a vaccine against Lassa hemorrhagic fever virus.
    Warner BM; Safronetz D; Stein DR
    Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
    mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever.
    Oestereich L; Rieger T; Lüdtke A; Ruibal P; Wurr S; Pallasch E; Bockholt S; Krasemann S; Muñoz-Fontela C; Günther S
    J Infect Dis; 2016 Mar; 213(6):934-8. PubMed ID: 26531247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects.
    Branco LM; Grove JN; Moses LM; Goba A; Fullah M; Momoh M; Schoepp RJ; Bausch DG; Garry RF
    Virol J; 2010 Nov; 7():306. PubMed ID: 21062490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.
    Cross RW; Mire CE; Branco LM; Geisbert JB; Rowland MM; Heinrich ML; Goba A; Momoh M; Grant DS; Fullah M; Khan SH; Robinson JE; Geisbert TW; Garry RF
    Antiviral Res; 2016 Sep; 133():218-222. PubMed ID: 27531367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Human Lassa Fever Is Characterized by Nonspecific T-Cell Activation and Lymphocyte Homing to Inflamed Tissues.
    Port JR; Wozniak DM; Oestereich L; Pallasch E; Becker-Ziaja B; Müller J; Rottstegge M; Olal C; Gómez-Medina S; Oyakhliome J; Ighodalo Y; Omomoh E; Olokor T; Adomeh DI; Asogun D; Ogbani-Emovon E; Hartmann K; Krasemann S; Nelson EV; Escudero-Pérez B; McElroy AK; Günther S; Muñoz-Fontela C
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
    Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lassa fever in post-conflict sierra leone.
    Shaffer JG; Grant DS; Schieffelin JS; Boisen ML; Goba A; Hartnett JN; Levy DC; Yenni RE; Moses LM; Fullah M; Momoh M; Fonnie M; Fonnie R; Kanneh L; Koroma VJ; Kargbo K; Ottomassathien D; Muncy IJ; Jones AB; Illick MM; Kulakosky PC; Haislip AM; Bishop CM; Elliot DH; Brown BL; Zhu H; Hastie KM; Andersen KG; Gire SK; Tabrizi S; Tariyal R; Stremlau M; Matschiner A; Sampey DB; Spence JS; Cross RW; Geisbert JB; Folarin OA; Happi CT; Pitts KR; Geske FJ; Geisbert TW; Saphire EO; Robinson JE; Wilson RB; Sabeti PC; Henderson LA; Khan SH; Bausch DG; Branco LM; Garry RF;
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2748. PubMed ID: 24651047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
    Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
    Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever.
    Mendenhall M; Russell A; Smee DF; Hall JO; Skirpstunas R; Furuta Y; Gowen BB
    PLoS Negl Trop Dis; 2011 Oct; 5(10):e1342. PubMed ID: 22022624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Common CD8
    Sakabe S; Hartnett JN; Ngo N; Goba A; Momoh M; Sandi JD; Kanneh L; Cubitt B; Garcia SD; Ware BC; Kotliar D; Robles-Sikisaka R; Gangavarapu K; Branco LM; Eromon P; Odia I; Ogbaini-Emovon E; Folarin O; Okogbenin S; Okokhere PO; Happi C; Sabeti PC; Andersen KG; Garry RF; de la Torre JC; Grant DS; Schieffelin JS; Oldstone MBA; Sullivan BM
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever.
    Raabe VN; Kann G; Ribner BS; Morales A; Varkey JB; Mehta AK; Lyon GM; Vanairsdale S; Faber K; Becker S; Eickmann M; Strecker T; Brown S; Patel K; De Leuw P; Schuettfort G; Stephan C; Rabenau H; Klena JD; Rollin PE; McElroy A; Ströher U; Nichol S; Kraft CS; Wolf T;
    Clin Infect Dis; 2017 Sep; 65(5):855-859. PubMed ID: 29017278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.
    Cashman KA; Smith MA; Twenhafel NA; Larson RA; Jones KF; Allen RD; Dai D; Chinsangaram J; Bolken TC; Hruby DE; Amberg SM; Hensley LE; Guttieri MC
    Antiviral Res; 2011 Apr; 90(1):70-9. PubMed ID: 21371508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.